The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination treatment of IO Biotech’s lead anti-cancer vaccine candidates IO102 and IO103, plus an anti-PD-1 antibody-based immunotherapy, to treat patients with inoperable or metastatic melanoma. This designation is given to accelerate the development, review, and possible approval of medications that aim to treat serious or life-threatening conditions and have the potential to provide significant advantages over current options. “This…
You must be logged in to read/download the full post.
The post Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapy appeared first on BioNewsFeeds.